Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | The value of alpha-synuclein as a putative target for therapeutic intervention in synucleinopathies

Tiago Outeiro, PhD, University Medical Center Göttingen, Göttingen, Germany, gives an update on the status of therapeutic strategies aimed at lowering and preventing the spread of alpha-synuclein pathology. A session at the International Congress of Parkinson’s Disease and Movement Disorders explored various approaches, including immunotherapy using antibodies to prevent protein aggregation, using small molecules to interfere with the aggregation process, and reducing alpha-synuclein production. The session emphasized the importance of understanding both the aggregation and loss of function aspects of alpha-synuclein and the need to consider future strategies to increase its function. Current efforts to reduce the spreading and aggregation of alpha-synuclein focus on immunotherapy and the use of antisense oligonucleotides to lower its production. Promising results have been seen in preclinical testing, but further clinical trials are needed to determine the efficacy of these approaches. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.